,40 A recent study suggests that olaparib maintenance therapy could bring survival benefits to metastatic pancreatic cancer patients with germline BRCA1/2 (gBRCA1/2) mutations.41 This evidence concerns the gene BRCA1 and pancreatic neoplasm.